Tough talks COVID-19 (TT-C) digital health intervention: multistate randomized controlled trial.

Publication date: Jul 01, 2025

During the COVID-19 pandemic, rapid changes in variant virulence, limited personal protective equipment availability, and diminished hospital capacity necessitated aggressive vaccine distribution. To promote COVID-19 vaccination to historically underserved populations, the National Institutes of Health funded a small group of clinical trials, including the Tough Talks for COVID-19 vaccine (TT-C) digital health intervention (DHI) randomized controlled trial (RCT). Black young adults, 18-29 years, who were unvaccinated or insufficiently vaccinated against COVID-19 were recruited via social media in Alabama, Georgia, and North Carolina and randomized to the intervention or standard of care control (N = 360). Self-report data and vaccine cards were collected at baseline, 1- and 3-months post-randomization. Post-intervention, 6. 4% received a new COVID-19 vaccine (8. 4% intervention; 4. 7% control). Odds of new COVID-19 vaccination were 1. 88 (CI: 0. 76, 4. 69, p = 0. 174) times higher in intervention compared to control participants adjusting for state. At 3 months post-randomziation, vaccine hesitancy was lower among intervention than control participants (CI:-0. 34,-0. 03, p = 0. 02), and vaccine confidence and vaccine knowledge were higher in intervention versus control participants (CI:0. 00,0. 32, p = 0. 05, CI:0. 21,0. 79, p = 0. 01 respectively). Under rapidly changing conditions, the TT-C DHI produced promising results on vaccine attitudes but not behaviors among Southern Black young adults. The intervention could be adapted to address vaccine uptake among other minority populations. Trial registration: NCT05490329, registered on 03082022. https://clinicaltrials. gov/study/NCT05490329 .

Open Access PDF

Concepts Keywords
Alabama Adolescent
Nct05490329 Adult
Pandemic African American
Underserved Alabama
Vaccinated Behavioral intervention
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Digital Health
Digital health
Female
Georgia
Humans
Male
MHealth
NIMHD research framework
North Carolina
SARS-CoV-2
Vaccination
Vaccine hesitancy
Young Adult
Young adults

Semantics

Type Source Name
disease MESH COVID-19
disease IDO intervention
disease IDO virulence
disease MESH emergency
disease IDO process
drug DRUGBANK Tropicamide
drug DRUGBANK Coenzyme M
disease MESH infection transmission
drug DRUGBANK Etoperidone
disease MESH allergies
disease MESH Educational attainment
pathway REACTOME Translation
disease MESH influenza
disease IDO site
drug DRUGBANK Isosorbide Mononitrate
drug DRUGBANK Dimethyl sulfone
disease MESH Morbidity
disease MESH violence
disease MESH uncertainty
drug DRUGBANK Gold
disease MESH AIDS
disease MESH STDs
disease IDO immunodeficiency
disease MESH Historical Trauma
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)